• 1
    Aleman BM,van den Belt-Dusebout AW,Klokman WJ,Van't Veer MB,Bartelink H,van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21: 34313449.
  • 2
    Hill DA,Gilbert E,Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005; 106: 33583365.
  • 3
    Gilbert E,Stovall M,Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res. 2003; 159: 161173.
  • 4
    U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002; 137: 129131. Comment in:Ann Intern Med.2003;138:356–357; author reply, 357. Summary for patients in:Ann Intern Med.2002;137:I38.
  • 5
    Swerdlow AJ,Barber JA,Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000; 18: 498509.
  • 6
    Bhatia S,Yasui Y,Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003; 21: 43864394.
  • 7
    Dores GM,Metayer C,Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20: 34843494.
  • 8
    Hodgson DC,Gilbert ES,Dores GM, et al. Long-term solid cancer risk among five-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007; 25: 14891497.
  • 9
    van Leeuwen FE,Klokman WJ,Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994; 12: 312325.
  • 10
    Engert A,Pluetschow A,Eich HT,Diehl V. Combined modality treatment of two or four cycles of ABVD followed by involved field radiotherapy in the treatment of patients with early stage Hodgkin's lymphoma: update interim analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). Blood. 2005; 106: 2673.
  • 11
    Eghbali E,Brice P,Cremmers GY, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F Trial. Blood. 2005; 106: 814.
  • 12
    Barton MB,Rose A,Lonergan D,Thornton D,O'Brien P,Trotter G. Mantle planning: report of the Australasian Radiation Oncology Lymphoma Group film survey and consensus guidelines. Australas Radiol. 2000; 44: 433438.
  • 13
    Koh ES,Tran TH,Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007; 2: 13.
  • 14
    Zellmer DL,Wilson JF,Janjan NA. Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. Int J Radiat Oncol Biol Phys. 1991; 21: 13431351.
  • 15
    Gray LH. A Symposium Considering Radiation Effects in the Cell and Possible Implications for Cancer Therapy: a Collection of Papers. Cellular Radiation Biology. Baltimore, Md: Williams & Wilkins; 1965: 825.
  • 16
    Mole RH. Ionizing radiation as a carcinogen: practical questions and academic pursuits. The Silvanus Thompson Memorial Lecture delivered at The British Institute of Radiology on April 18, 1974. Br J Radiol. 1975; 48: 157169.
  • 17
    van Leeuwen FE,Klokman WJ,Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003; 95: 971980.
  • 18
    Travis LB,Hill DA,Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003; 290: 465475.
  • 19
    Travis LB,Gilbert E. Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use. Radiat Res. 2005; 163: 695696.
  • 20
    Sachs RK,Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci U S A. 2005; 102: 1304013045.
  • 21
    Little MP. A multi-compartment cell repopulation model allowing for inter-compartmental migration following radiation exposure, applied to leukaemia. J Theor Biol. 2007; 245: 8397.
  • 22
    Shuryak I,Sachs RK,Hlatky L,Little MP,Hahnfeldt P,Brenner DJ. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks. J Natl Cancer Inst. 2006; 98: 17941806.
  • 23
    Lindsay KA,Wheldon EG,Deehan C,Wheldon TE. Radiation carcinogenesis modelling for risk of treatment-related second tumours following radiotherapy. Br J Radiol. 2001; 74: 529536.
  • 24
    Sacher GA,Trucco E. Theory of radiation injury and recovery in self-renewing cell populations. Radiat Res. 1966; 29: 236256.
  • 25
    Kry SF,Salehpour M,Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005; 62: 11951203.
  • 26
    Yahalom J. Radiation Field Design and Dose in Hodgkin's Disease and Non-Hodgkin's Lymphoma: New Concepts, New Tools [compact disc]. Educational Session 312. Educational Syllabus, 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Atlanta, GA, October 3–7, 2004.
  • 27
    U.S. National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results. SEER*Stat [computer program]. Version 6.1.4. Bethesda, Md: National Cancer Institute; April 14, 2005. Available at:
  • 28
    Lamarre L,Jacobson JO,Arsenberg AC, et al. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989; 13: 730739.
  • 29
    Health, United States, 2006. Washington, DC: U. S. Department of Health and Human Services; 2006.
  • 30
    Lew E,Garfinkel L. Differences in mortality and longevity by sex, smoking status and health status. Transact Soc Actuaries. 1987; 39: 107130.
  • 31
    Franklin J,Pluetschow A,Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006; 17: 17491760.
  • 32
    Girinsky T,van der Maazen R,Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006; 79: 270277.
  • 33
    Aisenberg AC,Finkelstein DM,Doppke KP,Koerner FC,Boivin JF,Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997; 79: 12031210.
  • 34
    van Leeuwen FE,Klokman WJ,Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000; 18: 487497.
  • 35
    Ng AK,Bernardo MV,Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002; 100: 19891996.
  • 36
    Foss Abrahamsen A,Andersen A,Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002; 13: 17861791.
  • 37
    Travis LB,Hill D,Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005; 97: 14281437.
  • 38
    Smitt MC,Stouffer N,Owen JB,Hoppe RT,Hanks GE. Results of the 1988–1989 Patterns of Care Study process survey for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1999; 43: 335339.
  • 39
    Hughes DB,Smith AR,Hoppe R, et al. Treatment planning for Hodgkin's disease: a patterns of care study. Int J Radiat Oncol Biol Phys. 1995; 33: 519524.
  • 40
    M'Kacher R,Girinsky T,Koscielny S, et al. Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys. 2003; 57: 321326.